Sound Education 101 — Integrative Oncology
You know about fenbendazole, ivermectin, and mebendazole. You've read the Joe Tippens story. You know about the work Dr. Makis is doing. The question on everyone's lips is — so where's the protocol?
If you've searched any of these, you're in the right place
The Answer You've Been Looking For
The reason you haven't been able to find a complete, definitive version of "The Protocol" — despite all your tireless searching — is not because it's being hidden from you. It's because a one-size-fits-all protocol was never possible in the first place.
Fenbendazole at 444mg twice daily is the target dose for some people. For someone with liver metastases, starting there could cause serious harm. Someone with Grade 2 NAFLD needs to start at a fraction of that dose with weekly monitoring before any escalation. And someone on enzalutamide may find that standard Ivermectin doses are rendered largely ineffective by the drug interaction — requiring either a dose adjustment or a conversation with their oncologist about substituting a non-interacting alternative.
And that's before we even get to interactions. Certain chemotherapy drugs, checkpoint inhibitors, anticoagulants, and targeted therapies change everything — what you can take, what you absolutely cannot, and what needs to be discussed with your oncologist before you start.
Protocols need to be tailored to your personal health profile in order to be safe, effective, and sustainable. That's not a disclaimer — it's the whole point.
The researchers, the case reports, the clinical trials — they all point to the same compounds. But the dosing, the cycling, the sequencing, the contraindications — those are personal. That's what nobody online has been able to give you. Until now.
What This Tool Does
What You Receive
Published Research Foundation
Every compound recommendation in this tool is grounded in published, peer-reviewed research. The following represents a selection of the key studies underpinning the protocol — from preclinical mechanisms through to clinical trial data and real-world outcome studies.
Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol.
Journal of Orthomolecular Medicine, 2024 — The first peer-reviewed publication of the combined Ivermectin, Mebendazole, and Fenbendazole protocol in oncology.
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.
Anticancer Research, 2026 — 190+ patients. 84.4% reported clinical benefit at 6-month follow-up including no evidence of disease, tumour shrinkage, or stable disease.
Ivermectin, Mebendazole and Fenbendazole in the Treatment of Cancer.
International Journal of Scientific Research, 2025.
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer.
ASCO Annual Meeting, 2025 — 37.5% clinical benefit rate. First major US institutional clinical trial data.
Ivermectin as an Inhibitor of Cancer Stem-Like Cells.
Molecular Medicine Reports, 2018.
A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose Ivermectin in Cancer Treatment?
Pharmacological Research, 2022.
Ivermectin Combined with Recombinant Methioninase Synergistically Eradicates Pancreatic Cancer Cells.
Anticancer Research, 2024.
Antiparasitic Mebendazole Shows Survival Benefit in 2 Preclinical Models of Glioblastoma Multiforme.
Neuro-Oncology, 2011 — Johns Hopkins University. The foundational GBM paper underpinning the Mebendazole brain tumour protocol.
Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.
Cancers (Basel), 2019.
Repositioning of the Anthelmintic Drug Mebendazole for the Treatment of Colon Cancer.
Journal of Cancer Research and Clinical Oncology, 2013.
Repurposing Mebendazole Against Triple-Negative Breast Cancer CNS Metastasis.
Pharmacological Research, 2024.
Fenbendazole Acts as a Moderate Microtubule Destabilizing Agent and Causes Cancer Cell Death by Modulating Multiple Cellular Pathways.
Scientific Reports, 2018 — The foundational mechanistic paper behind the Joe Tippens protocol.
The Role of HO-1 and Its Crosstalk with Oxidative Stress in Cancer Cell Survival.
Cells, 2021.
A Novel Treatment to Enhance Survival for End Stage Triple Negative Breast Cancer Using Repurposed Veterinary Anthelmintics Combined with Gut-Supporting and Immune Enhancing Molecules.
Frontiers in Oncology, 2023.
NCT05318469 — Phase II: Ivermectin with Immunotherapy for Breast Cancer (recruiting)
NCT07487805 — ICONIC Trial: Ivermectin Combined with Immune Checkpoint Inhibition in Cancer
NCT03925662 — Phase 2/3: Mebendazole as Adjuvant Treatment for Stage 4 Colon Cancer (recruiting)
NCT02644291 — Phase I: Mebendazole for Recurrent Paediatric Brain Tumours (completed)
This reference list represents a selection of the published evidence base. Evidence levels vary between studies — from preclinical mechanistic research through to Phase I/II clinical trials and prospective observational cohorts. This tool presents research reference information only. Always discuss with your oncologist and pharmacist before acting on any information.
The more information you can provide, the more tailored your protocol will be. If you're doing this for a loved one, it's worth gathering the following before you begin. You can always run the generator again as new information becomes available.
Cancer type, stage, and grade
Including any known mutations — KRAS, EGFR, HER2, MGMT methylation, MSI status — and whether brain involvement is present.
Current medications and doses
Every prescription medication — including chemotherapy, immunotherapy, hormonal therapy, pain medications, antidepressants, anticoagulants, and diabetes medications. This is the most important input for the interaction checker.
Recent blood test results
Particularly ALT and AST (liver enzymes), ANC (absolute neutrophil count), haemoglobin, and bilirubin if available. These determine your liver grade and directly affect starting doses.
Current treatment
Chemotherapy regimen, immunotherapy (checkpoint inhibitors), radiation, hormonal therapy, or surgical history — all affect which compounds are appropriate and how they should be timed.
Body weight and age
Ivermectin dosing is calculated by body weight in kg. Age affects melatonin dosing thresholds.
Known allergies and comorbidities
Including liver disease, fatty liver (NAFLD), kidney conditions, autoimmune disease, G6PD deficiency, and diabetes — all of which affect compound selection and dosing.
Not sure what to expect?
Eight test patient profiles are included with your subscription.
Covering a range of cancer types, medications, and clinical situations — from Stage 4 NSCLC with liver metastases to GBM, prostate cancer on enzalutamide, ER+ HER2+ breast cancer, CLL on venetoclax, and more. Run any of them to see exactly what a personalised protocol looks like before you enter your own details.
Enter your details. Get your personalised reference document.
Take it to your next appointment.
Already subscribed? Sign in here →
Please adhere to all monitoring schedules and disclose all medications and supplements to your doctor.
This tool provides research reference information only. It does not constitute medical advice, diagnosis, or treatment. All output must be reviewed with your oncologist and oncology pharmacist before acting on any information. This tool does not provide guidance on sourcing or purchasing any compound. Sound Education 101 is an educational resource — always consult qualified healthcare professionals regarding your treatment.
Sound Education 101 is not a licensed medical doctor, pharmacist, naturopathic doctor, nutritionist, or other formally licensed healthcare professional or provider of any kind. Sound Education 101 does not render medical, psychological, or other professional advice or treatment, nor does it provide or prescribe any medical diagnosis, treatment, medication, or remedy. Nothing on this platform should be considered a promise of benefits, a claim of cures, a legal warranty, or a guarantee of results to be achieved.
No statement, claim, or representation made on or accessible from this website has been evaluated by the Therapeutic Goods Administration (TGA), the United States Food and Drug Administration (FDA), or any other regulatory authority. No compound, product, or supplement mentioned on this platform is intended to diagnose, treat, cure, or prevent any disease.
Access to or use of this tool does not constitute a client, patient, or professional relationship between the user and Sound Education 101. Information provided on this platform does not guarantee to be correct, complete, or up to date. You should not alter or discontinue any current medications, treatment, or care based on information from this tool without first consulting your qualified healthcare provider.